

## Parsed Citations

**NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine. 1995;333:1581-1587.**

PubMed: <http://www.ncbi.nlm.nih.gov/pubmed/7477192?dopt=abstract>

CrossRef: <http://dx.doi.org/10.1056%2FNEJM199512143332401>

Google Scholar: [Author Only Title Only Author and Title](#)

**Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.**

PubMed: <http://www.ncbi.nlm.nih.gov/pubmed/18815396?dopt=abstract>

Google Scholar: [Author Only Title Only Author and Title](#)

**Kleindorfer D LC, White G, Curtis T, Brass L, Koroshetz W, Broderick JP. National us estimates of rt-pa use: Icd-9 codes substantially underestimate. Stroke. 2008;39:924-928.**

PubMed: <http://www.ncbi.nlm.nih.gov/pubmed/18239184?dopt=abstract>

CrossRef: <http://dx.doi.org/10.1161%2FSTROKEAHA.107.490375>

Google Scholar: [Author Only Title Only Author and Title](#)

**Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the united states: A doubling of treatment rates over the course of 5 years. Stroke. 2011;42:1952-1955.**

PubMed: <http://www.ncbi.nlm.nih.gov/pubmed/21636813?dopt=abstract>

CrossRef: <http://dx.doi.org/10.1161%2FSTROKEAHA.110.612358>

Google Scholar: [Author Only Title Only Author and Title](#)

**Kleindorfer D, Xu Y, Moomaw CJ, Khatri P, Adeoye O, Hornung R. Us geographic distribution of rt-pa utilization by hospital for acute ischemic stroke. Stroke. 2009;40:3580-3584.**

PubMed: <http://www.ncbi.nlm.nih.gov/pubmed/19797701?dopt=abstract>

CrossRef: <http://dx.doi.org/10.1161%2FSTROKEAHA.109.554626>

Google Scholar: [Author Only Title Only Author and Title](#)

**Kleindorfer D, Mullen M, Hogan C, Adeoye O, Khatri P, Jauch E. Primary stroke center certification and its impact on thrombolysis use. Stroke abstract. 2012.**

Google Scholar: [Author Only Title Only Author and Title](#)

**Kleindorfer D, Kissela B, Schneider A, Woo D, Khoury J, Miller R, et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: A population-based study. Stroke. 2004;35:e27-29.**

CrossRef: <http://dx.doi.org/10.1161%2F01.STR.0000109767.11426.17>

Google Scholar: [Author Only Title Only Author and Title](#)

**Kleindorfer DO, Broderick JP, Khoury J, Flaherty ML, Woo D, Alwell K, Moomaw CJ, et al. Emergency department arrival times after acute ischemic stroke during the 1990s. Neurocrit Care. 2007;7:31-35.**

PubMed: <http://www.ncbi.nlm.nih.gov/pubmed/17622492?dopt=abstract>

Google Scholar: [Author Only Title Only Author and Title](#)

**Majersik JJ, Smith MA, Zahuranec DB, Sanchez BN, Morgenstern LB. Population-based analysis of the impact of expanding the time window for acute stroke treatment. Stroke. 2007;38:3213-3217.**

CrossRef: <http://dx.doi.org/10.1161%2FSTROKEAHA.107.491852>

Google Scholar: [Author Only Title Only Author and Title](#)

**Khatri P KJ, Alwell K, Moomaw CJ, Kissela BM, Woo D, Flaherty ML, et al. T Stroke and Cerebral Circulation, Los Angeles, CA (February 2011). He public health impact of an effective acute treatment for mild ischemic strokes. Stroke abstract. 2011.**

Google Scholar: [Author Only Title Only Author and Title](#)

**Del Zoppo GJ, Saver JL, Jauch EC, Adams HP, Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: A science advisory from the american heart association/american stroke association. Stroke. 2009;40:2945-2948.**

PubMed: <http://www.ncbi.nlm.nih.gov/pubmed/19478221?dopt=abstract>

CrossRef: <http://dx.doi.org/10.1161%2FSTROKEAHA.109.192535>

Google Scholar: [Author Only Title Only Author and Title](#)

**de Los Rios la Rosa F, Khoury J, Kissela BM, Flaherty ML, Alwell K, Moomaw CJ, et al. Eligibility for intravenous recombinant tissue-type plasminogen activator within a population: The effect of the european cooperative acute stroke study (ecass) iii trial. Stroke. 2012;43:1591-1595.**

CrossRef: <http://dx.doi.org/10.1161%2FSTROKEAHA.111.645986>

Google Scholar: [Author Only Title Only Author and Title](#)